Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04536077 · ClinicalTrials.gov registry record · Phase 2
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04536077 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 16 participants.
The verdict
NCT04536077, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.
Interventions
- DRUG CDX-1140
- DRUG CDX-301
- PROCEDURE Research blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-08-13 |
| Est. Completion | 2023-11-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04536077
The ClinicalTrials.gov registry entry for NCT04536077 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CDX-1140 is the first listed.
NCT04536077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04536077 about?
NCT04536077 is a clinical study titled "Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients". The central hypothesis is that the addition of CDX-301 to CDX-1140 radically improves anti-tumor immunity in patients with pancreatic ductal adenocarcinoma.
What is the current status of trial NCT04536077?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-08-13. Estimated completion is 2023-11-21.
What interventions are being tested in trial NCT04536077?
The interventions under investigation include: CDX-1140 (DRUG), CDX-301 (DRUG), Research blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT04536077?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.